about
Profile of evolocumab and its potential in the treatment of hyperlipidemiaClinical perspectives of anti-inflammatory therapy in the elderly: the lipoxigenase (LOX)/cycloxigenase (COX) inhibition conceptRole of phytochemicals in the management of metabolic syndrome.Tinnitus in elderly patients and prognosis of mild-to-moderate congestive heart failure: a cross-sectional study with a long-term extension of the clinical follow-up.Serum uric acid is inversely proportional to estimated stroke volume and cardiac output in a large sample of pharmacologically untreated subjects: data from the Brisighella Heart Study.Population health needs assessment and healthcare services use in a 3 years follow-up on administrative and clinical data: results from the Brisighella Heart Study.Association between serum uric acid, hypertension, vascular stiffness and subclinical atherosclerosis: data from the Brisighella Heart Study.Safety and tolerability of injectable lipid-lowering drugs: a review of available clinical data.Serum uric acid and impaired cognitive function in a cohort of healthy young elderly: data from the Brisighella Study.Combinations of phytomedicines with different lipid lowering activity for dyslipidemia management: The available clinical data.Fixed combination of zofenopril plus hydrochlorothiazide in the management of hypertension: a review of available data.Recommendations for the treatment of hypertension in patients with DM: critical evaluation based on clinical trials.Adipokines and sexual hormones associated with the components of the metabolic syndrome in pharmacologically untreated subjects: data from the brisighella heart study.Psychosocial factors and metabolic parameters: is there any association in elderly people? The Massa Lombarda Project.Cocoa bioactive compounds: significance and potential for the maintenance of skin health.Hyperuricemia and cardiovascular disease risk.Can Phyllanthus niruri affect the efficacy of extracorporeal shock wave lithotripsy for renal stones? A randomized, prospective, long-term study.Bioactive peptides in cereals and legumes: agronomical, biochemical and clinical aspects.Cerebrovascular disease in Italy and Europe: it is necessary to prevent a 'pandemia'.Potential benefits of berberine in the management of perimenopausal syndrome.Hepatitis C virus recurrence after liver transplantation: a 10-year evaluation.Relationship between serum uric acid and electrocardiographic alterations in a large sample of general population: data from the Brisighella Heart Study.Short-term effects of a combined nutraceutical of insulin-sensitivity, lipid level and indexes of liver steatosis: a double-blind, randomized, cross-over clinical trial.25-Hydroxy vitamin D levels and endothelial vasodilator function in normotensive womenWhat do herbalists suggest to diabetic patients in order to improve glycemic control? Evaluation of scientific evidence and potential risks.Testing the Short-Term Efficacy of a Lipid-Lowering Nutraceutical in the Setting of Clinical Practice: A Multicenter StudyMiddle and Long-Term Impact of a Very Low-Carbohydrate Ketogenic Diet on Cardiometabolic Factors: A Multi-Center, Cross-Sectional, Clinical Study.Impact of physical activity on inflammation: effects on cardiovascular disease risk and other inflammatory conditions.Metformin and its clinical use: new insights for an old drug in clinical practice.Do the lactotripeptides isoleucine-proline-proline and valine-proline-proline reduce systolic blood pressure in European subjects? A meta-analysis of randomized controlled trialsInfluence of metabolic syndrome superposition on familial combined hyperlipoproteinemia cardiovascular complication rateRationale for the use of a fixed-dose combination in the management of hypertension: efficacy and tolerability of lercanidipine/enalapril.Preclinical and clinical evidence of nephro- and cardiovascular protective effects of glycosaminoglycans.Tolerability and safety of commonly used dietary supplements and nutraceuticals with lipid-lowering effects.Hyperthyroidism and cardiovascular complications: a narrative review on the basis of pathophysiology.Efficacy and safety profile of evolocumab (AMG145), an injectable inhibitor of the proprotein convertase subtilisin/kexin type 9: the available clinical evidence.Inner ear symptoms: can we use them to approach cardiovascular diseases?Combination therapy in the extended cardiovascular continuum: a focus on perindopril and amlodipine.RETRACTED: Acarbose on insulin resistance after an oral fat load: a double-blind, placebo controlled study.The cost-effectiveness of irbesartan for hypertension.
P50
Q27004235-DB3E47C3-EA1F-4FAC-B243-0AAB4321452BQ28168113-3E5D0637-0F91-4635-9729-446DC50861D5Q30251959-13DB6C4D-1847-4A13-B1E9-DC0CC7BB0118Q30474748-A03B7C61-4254-494D-9034-2A462231A5B3Q30691881-E966D923-1C99-45F5-BE85-8C708E6F19FAQ30696589-120B737F-9C18-48DC-BC55-73D922CEBC6EQ30708800-AC665D15-6A54-4B56-A8DE-D5882985BBCBQ30833167-427DC183-3A39-45B3-8EBC-3A3099229314Q30834519-2696C53F-6877-433A-8BDC-203F65B7C9BAQ31029500-FAF552AB-0120-4396-9EFB-9F119A0EB4D0Q31102886-605C1F47-1A5C-4B2E-8201-12C9508CB27BQ33356154-DCEA942A-94A1-4185-992F-8A6DF3784ECDQ34082707-AD20140D-F45A-441E-A4FC-2EE335D0531EQ34084777-FC9E6259-4085-404F-B672-3BA55CC49730Q34091782-A0875CD0-188A-4092-A039-50FB9889E9FBQ34437057-250F91DB-112D-403A-870B-EE96E63A3A28Q34554541-8E436524-2B69-4454-B651-033E2B1275A5Q34685653-E15677FE-CC42-4341-987C-74ADAD115F8BQ35062687-C1288027-6E28-47F1-B2D7-11FE57772A91Q35138347-A30E0E30-21D8-46B8-B9BE-DB838D8B022DQ35270256-39EFAC93-38A8-42E1-8C50-FA3548C1206AQ35523790-E052A30D-1803-40F7-8717-A04D3F4071C8Q35541371-7503D907-EBCD-4868-AD11-2065034403FEQ35843930-2B55402E-1356-43C7-812E-89B4029CB6A7Q36018109-F5B88EE2-E6DF-472A-AD3D-8DEEF5CCA820Q36263531-73F0049E-E65F-4571-AE28-FB973C771405Q36339108-EDD0689C-42BC-4158-867D-FBB6717BE775Q36423044-0029766D-7505-4416-8E4C-FD72B3512C08Q36423076-D5ABFFEB-C5C9-4CC0-A7A1-252F71A06DF5Q36590794-680BA2F3-38E9-4B7E-813D-3E4828E2F90FQ36829050-2E5956BE-6FFB-4C73-B2D7-48C7FDC8A6F7Q37798001-2FA3A736-595E-48D6-B3DA-1CBB5F8AAAA8Q37988853-A4BD4006-CFA1-4997-B2E4-371DBD862EA1Q38025713-6A774646-027A-41E0-877F-8397A58647F9Q38165941-4F252ABD-8F79-4027-B929-23D37B4CF565Q38198739-BC01A15D-0D08-4E63-AE2B-3CC4A54C97FFQ38253545-09E3079B-CA1D-4FF5-9696-CC1AB68DF911Q38319206-C5876781-C22A-4814-8A02-FDD79D07BE66Q38336973-21C419E0-16FE-4CB5-A9F6-5F1E6803D7A7Q38363840-AFE1F6AD-50A5-4264-BD70-F3258DCF9ED5
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Arrigo F. Cicero
@en
Arrigo F. Cicero
@es
Arrigo F. Cicero
@nl
Arrigo Francesco Giuseppe Cicero
@de
type
label
Arrigo F. Cicero
@en
Arrigo F. Cicero
@es
Arrigo F. Cicero
@nl
Arrigo Francesco Giuseppe Cicero
@de
prefLabel
Arrigo F. Cicero
@en
Arrigo F. Cicero
@es
Arrigo F. Cicero
@nl
Arrigo Francesco Giuseppe Cicero
@de
P214
P227
P101
P106
P1153
7003403707
P21
P214
P227
1137019468
P2798
P31
P496
0000-0002-4367-3884
P5008
P7859
viaf-311811493